Ribonucleotide reductase inhibitors suppress SAMHD1 ara‐CTPase activity enhancing cytarabine efficacy

The deoxycytidine analogue cytarabine (ara‐C) remains the backbone treatment of acute myeloid leukaemia (AML) as well as other haematological and lymphoid malignancies, but must be combined with other chemotherapeutics to achieve cure. Yet, the underlying mechanism dictating synergistic efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Rudd, Sean G, Tsesmetzis, Nikolaos, Sanjiv, Kumar, Paulin, Cynthia BJ, Sandhow, Lakshmi, Kutzner, Juliane, Hed Myrberg, Ida, Bunten, Sarah S, Axelsson, Hanna, Zhang, Si Min, Rasti, Azita, Mäkelä, Petri, Coggins, Si'Ana A, Tao, Sijia, Suman, Sharda, Branca, Rui M, Mermelekas, Georgios, Wiita, Elisée, Lee, Sun, Walfridsson, Julian, Schinazi, Raymond F, Kim, Baek, Lehtiö, Janne, Rassidakis, Georgios Z, Pokrovskaja Tamm, Katja, Warpman‐Berglund, Ulrika, Heyman, Mats, Grandér, Dan, Lehmann, Sören, Lundbäck, Thomas, Qian, Hong, Henter, Jan‐Inge, Schaller, Torsten, Helleday, Thomas, Herold, Nikolas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059017/
https://www.ncbi.nlm.nih.gov/pubmed/31950591
http://dx.doi.org/10.15252/emmm.201910419

Ejemplares similares

Ejemplares similares